Projected Price to Earnings: metaviatx.com (MTVA)
MetaVia Inc (MTVA) is currently testing its neurodisorder treatments while maintaining strict control over R&D expenditures. The company's forward P/E ratio on this GURU.Markets chart confirms this, where the value 0.00 aligns with the current metric. The business model relies on full production outsourcing, while its environmental strategy is implemented through research bioethics and energy-efficient laboratory processes.
Analytical breakdowns and data insights for company MetaVia, Inc. (MTVA)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and solvency information:
- earnings and market ratios statistics:
MTVA - Company Profit|Projected Future Earnings MetaVia Inc|MTVA - Price to Earnings Ratio|Future Price to Earnings MetaVia Inc|MTVA - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio MetaVia, Inc.|MTVA - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months MetaVia|MTVA - Earnings per share for the last twelve months|Quarterly EPS earnings growth metaviatx.com|MTVA - Earnings growth in current year|Net earnings per share growth forecast for next year MetaVia Inc
Comprehensive company analysis:MetaVia MTVA
The forward P/E determines the ratio of MetaVia Inc. (MTVA) current market capitalization to expected annual earnings, measuring market optimism regarding profit growth rates. By analyzing the company's valuation via the forward P/E, an investor determines the asset's margin of safety, where low values confirm an undervaluation of the potential for precision medicine and innovative therapies for complex metabolic disorders within the business structure.
Direct competitors
Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Regencell - Projected Price to Earnings|Market Cap to Future Earnings Ratio AXSM (Axsome Corp)|ACADIA Pharmaceuticals - Forward P/E Multiple|XENE - Forward P/E Multiple|VKTX (Viking Therapeutics, Inc.) - Projected Price to Earnings|SUPN (Supernus Pharmaceuticals, Inc.) - Future Price to Earnings|CPRX (Catalyst Pharmaceuticals Inc) - Forward P/E Multiple|Denali Corp (DNLI) - Market Cap to Projected Earnings|Forward P/E Multiple HRMY|Forward P/E Multiple biohavenpharma.com (BHVN)|Amylyx Pharmaceuticals, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple TRVI|Praxis Medicines - Forward P/E Multiple|Market Cap to Projected Earnings Anavex Life Sciences Corp AVXL|CeriBell, Inc. (CBLL) - Future Price to Earnings|Price to Future Earnings Ratio PRTA|ALEC (Alector Inc.) - Forward P/E Multiple|Projected Price to Earnings Annexon Biosciences (ANNX)|Future Price to Earnings Omeros Corporation (OMER)|Projected Price to Earnings Neurogene Therapeutics NGNE|AC Immune - Projected Price to Earnings|Market Cap to Future Earnings Ratio VYGR (voyagertherapeutics.com)|NMRA: Projected Price to Earnings|SCLX: Future Price to Earnings|TVGN: Forward P/E Multiple|Alpha Cognition Inc. (ACOG) - Forward P/E Multiple|Future Price to Earnings Cognition Therapeutics|Price to Future Earnings Ratio IKT (inhibikase.com)|Forward P/E Multiple SAVA|ASRT - Projected Price to Earnings Ratio|Coya Therapeutics - Projected Price to Earnings|Forward P/E Multiple VistaGen Therapeutics, Inc. VTGN|OVID - Future Price to Earnings|Future Price to Earnings Multiple ABOS (acumenpharm.com)|CervoMed (CRVO) - Future Price to Earnings|Projected Price to Earnings Ratio Alterity Therapeutics Limited (ATHE)|Future Price to Earnings Clene Inc|Projected Price to Earnings PepGen Corp (PEPG)|Forward P/E Multiple JUNS|RLMD - Projected Price to Earnings Ratio|Annovis Bio - Projected Price to Earnings|Market Cap to Future Earnings Ratio GRCE (Grace Therapeutics Inc)|Firefly Neuroscience Inc - Forward P/E Multiple|KLTO - Forward P/E Multiple|NRSN (neurosense-tx.com) - Projected Price to Earnings|RVPH (revivapharma.com) - Future Price to Earnings|NRXS (NeurAxis) - Forward P/E Multiple|Helius Medical Technologies Inc. (HSDT) - Market Cap to Projected Earnings|Forward P/E Multiple PASG|Forward P/E Multiple bionomics.com.au (NEUP)|Minerva Neurosciences - Projected Price to Earnings|Future Price to Earnings Multiple ATHA|Addex Therapeutics Ltd - Forward P/E Multiple|Market Cap to Projected Earnings Alzamend Neuro, Inc. ALZN|cyclerion.com (CYCN) - Future Price to Earnings|Price to Future Earnings Ratio PTIX|KTTA (Pasithea Therapeutics Corp) - Forward P/E Multiple|Projected Price to Earnings Cortigent Medical (CRGT)|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|Projected Price to Earnings Brainstorm Cell Therapeutics Inc. BCLI|Cara Therapeutics, Inc - Projected Price to Earnings|Market Cap to Future Earnings Ratio CHRO (Chromocell)|ELYM: Projected Price to Earnings|ITCI: Future Price to Earnings|LBPH: Forward P/E Multiple|Marinus Pharmaceuticals Inc (MRNS) - Forward P/E Multiple|Future Price to Earnings NKGen|Price to Future Earnings Ratio NRBO (NeuroBo Pharma)|Forward P/E Multiple SAGE|SNPX - Projected Price to Earnings Ratio|Trevena - Projected Price to Earnings|Forward P/E Multiple Vigil Neuroscience Inc. VIGL|WENA - Future Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Corp)
